BioNTech, Ryvu collaborate on small molecule immuno-modulatory therapies
Under the collaboration, the two companies will jointly develop several small molecule programmes, primarily targeting immune modulation in…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
01 Dec 22
Under the collaboration, the two companies will jointly develop several small molecule programmes, primarily targeting immune modulation in…
17 Oct 22
The funding will help to generate new treatments and improve the delivery of healthcare services to support experimental…
14 Oct 22
The new financing will allow Odyssey Therapeutics to advance its portfolio of precision immunomodulators and oncology medicines, supporting…
12 Oct 22
The strategic research collaboration will combine Illumina and AstraZeneca’s combined strengths in artificial intelligence (AI) based genome interpretation…
21 Sep 22
Pfizer has used CytoReason's biological models in its research to improve the understanding of the immune system and…
07 Apr 22
The transaction will create a vertically integrated platform and cardiovascular disease franchise, which will support the discovery and…
11 Mar 22
Xcellomics programme was created by the two Oxford-based institutions to advance the early-stage drug discovery research by academic…
11 Feb 22
The US drugmaker has used several insights from the CytoReason’ platform, in several of its R&D programmes across…
10 Feb 22
The investment round, jointly led by SoftBank Vision Fund 2 and RA Capital Management, will advance the company’s…
23 Dec 21
The acquisition will enable Novartis to add Gyroscope’s investigational gene therapy, GT005, to its portfolio